Asthma: Analysis of key marketed drugs.
By Natasha Spiller, Analyst
24 July 2014
I am an Analyst at Datamonitor Healthcare. After joining the company in 2012, I have produced analysis across a number o...
Read full bio
Two key marketed drugs, Advair and Symbicort, will face erosion in sales due to the emergence of Breo and other generics emerging from the pipeline. Datamonitor Healthcare has provided an in-depth analysis of key marketed products in the US, Japan, and five major EU markets, including an assessment of product positioning in the face of pipeline competition and an evaluation of clinical and commercial drug attributes.
How will our asthma marketed drugs report benefit you?
- Gain competitive insight
Access detailed analyses of key marketed drugs within asthma, including an assessment of product positioning in the face of pipeline competition and an evaluation of commercial and clinical drug attributes to determine competitiveness in the market.
- Understand market share
Explore how the emergence of Breo and other generics will affect sales of established drugs such as Advair and Symbicort, allowing you to gain a better understanding of your position within the market.
- Identify driving forces behind the asthma market
Examine how novel therapies such as Breo, the first once-daily inhaled corticosteroid/long-acting beta 2 agonist, and Xolair, the only biologic for asthma, are positioned within the market so that you can identify what factors are critical for commercial success.
Key questions answered
- What clinical trials led to regulatory approval of key marketed brands?
- What factors will enable marketed brands to resist generic erosion?
- Will GlaxoSmithKline retain its dominance within the asthma market?
|Drug List:||Companies Mentioned:|
Posted in Respiratory.